je.st

Home › continued

Tag: continued

6 Nov 21 continued testimony

2016-11-29 23:29:42| PortlandOnline

PDF Document, 14,829kbCategory: Residential Infill Project - council documents

Sony quarterly results fall on continued drop in smartphones

2016-11-01 08:31:00| Telecompaper Headlines

(Telecompaper) Sony reported revenues for its fiscal second quarter to September down 10.8 percent year-on-year to JPY 1.689 trillion, hurt by the continued drop in sales of its smartphones. Excluding currency effects, revenues were essentially flat, as the lower mobile sales were offset by growth in financial services and films. Operating profit fell to JPY 45.7 billion from JPY 88.0 billion a year earlier, led by lower results from semiconductors and components, and net profit dropped to JPY 4.8 billion from JPY 33.6 billion. The results include the earlier announced impairment charge on the battery business up for sale and continued repair costs for the earthquake early this year.

Tags: results fall sony continued

Evaluation of EU's Antimicrobials Plan Shows Continued Efforts Needed

2016-10-26 02:00:00| ThePigSite - Industry News

EU - The EU's evaluation of its Antimicrobial Resistance (AMR) Action Plan (2011-2016) has shown that while progress has been made, continued efforts are required to address the problem.

Tags: plan needed shows continued

KEYTRUDA (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress

2016-10-09 08:15:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months compared to standard of care chemotherapy (docetaxel) in patients with metastatic non-small cell lung cancer (NSCLC) previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1 (tumor proportion score [TPS] of one percent or more), as well as patients with high levels Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data longer presented cell